Sandostatin LAR

DRUG9 trials

Conditions

AcromegalyAdvanced CancerGEP-NETHyperphagiaNeuroendocrine TumorsObesityPrader-Willi Syndrome

Phase 1

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

TerminatedNCT05364944

Debiopharm International SAAcromegaly, GEP-NET

Start: 2022-05-18End: 2024-12-03Updated: 2025-11-17

Phase 2

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

CompletedNCT01744249

Grupo Espanol de Tumores NeuroendocrinosAdvanced Cancer, Neuroendocrine Tumors

Start: 2011-11-01End: 2023-12-31Updated: 2026-04-28

A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly

CompletedNCT07814651

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Acromegaly

Start: 2024-04-16End: 2026-04-23Updated: 2026-09-11

Phase 3

Prader-Willi Syndrome and Appetite

TerminatedNCT00175305

University of British ColumbiaHyperphagia, Prader-Willi Syndrome

Start: 2004-08-31End: 2007-10-31Target: 10Updated: 2007-10-31

Phase 4

Pegvisomant And Sandostatin LAR Combination Study

CompletedNCT00068029

PfizerAcromegaly

Start: 2003-10-31End: 2006-05-31Target: 75Updated: 2008-04-07

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

CompletedNCT00068042

PfizerAcromegaly

Start: 2003-04-30End: 2006-05-31Target: 100Updated: 2008-04-07

Pediatric Hypothalamic Obesity

CompletedNCT00076362

Novartis PharmaceuticalsObesity

Start: 2004-03-31Updated: 2011-09-12

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

CompletedNCT01278342

Novartis PharmaceuticalsAcromegaly

Start: 2006-09-30End: 2009-11-30Updated: 2017-03-03

Effects of Sandostatin LAR® in Acromegaly

CompletedNCT01424241

Columbia UniversityAcromegaly

Start: 2006-10-31End: 2014-01-31Updated: 2024-07-24

Related Papers

Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival

European Journal of Endocrinology2023-11-3010 citations

A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107).

Journal of Clinical Oncology2021-01-2035 citations